Abstract
Background:
Barrett’s esophagus (BE) is a precursor of esophageal adenocarcinoma. It is critical to recognize the risk factors associated with BE.
Objectives:
The present meta-analysis aims to systematically estimate the association of hiatal hernia with the risk of BE.
Design:
A meta-analysis with trial sequential analysis.
Data sources and methods:
The PubMed, EMBASE, and Cochrane Library databases were searched. The pooled odds ratios (ORs) and adjusted ORs (aORs) with their 95% confidence intervals (CIs) were calculated for the combined estimation of unadjusted data and data adjusted for confounders, respectively. Heterogeneity was quantified using the Cochrane Q test and I² statistics. Subgroup, meta-regression, and leave-one-out sensitivity analyses were employed to explore the sources of heterogeneity.
Results:
Forty-seven studies with 131,517 participants were included. Based on the unadjusted data from 47 studies, hiatal hernia was significantly associated with an increased risk of any length BE (OR = 3.91, 95% CI = 3.31–4.62, p < 0.001). The heterogeneity was significant (I² = 77%; p < 0.001) and the definition of controls (p = 0.014) might be a potential contributor to heterogeneity. Based on the adjusted data from 14 studies, this positive association remained (aOR = 3.26, 95% CI = 2.44–4.35, p < 0.001). The heterogeneity was also significant (I² = 65%; p < 0.001). Meta-analysis of seven studies demonstrated that hiatal hernia was significantly associated with an increased risk of long-segment BE (LSBE) (OR = 10.01, 95% CI = 4.16–24.06, p < 0.001). The heterogeneity was significant (I² = 78%; p < 0.001). Meta-analysis of seven studies also demonstrated that hiatal hernia was significantly associated with an increased risk of short-segment BE (OR = 2.76, 95% CI = 2.05–3.71, p < 0.001). The heterogeneity was not significant (I² = 30%; p = 0.201).
Conclusion:
Hiatal hernia should be a significant risk factor for BE, especially LSBE.
Registration:
PROSPERO registration number CRD42022367376.
Keywords: Barrett’s esophagus, esophageal adenocarcinoma, gastroesophageal reflux disease, hiatal hernia, meta-analysis
Graphical abstract
Introduction
Barrett’s esophagus (BE), a major complication of gastroesophageal reflux disease (GERD), is defined as an abnormal condition in which normal esophageal squamous epithelium has been replaced by columnar-lined epithelium with histological evidence of specialized intestinal metaplasia. 1 BE is the only known precursor lesion for the development of esophageal adenocarcinoma (EAC). It is estimated that about 0.33% of BE individuals progress to EAC annually worldwide 2 and the risk of EAC among BE patients is 10- to 55-fold higher as compared to the general population. 3 BE is usually asymptomatic in nature and can only be diagnosed by endoscopy, therefore, its estimated prevalence in the population remains difficult to assess. 4 Existing risk factors for BE include gastroesophageal reflux symptoms, male, age greater than 50 years, white race, increased body mass index, and/or central adiposity, smoking, and family history.1,5–8
Hiatal hernia is a common digestive disease with acid regurgitation, heartburn, and chest pain as the predominant manifestations, which refers to protrusion of stomach or other abdominal viscera through the esophageal hiatus of the diaphragm into the mediastinum. 9 It has been divided into four types based on the currently recognized anatomical classification. Type 1 hiatal hernia is the most prevalent type, accounting for more than 90% of cases of hiatal hernia, also termed a sliding hiatal hernia; and types 2–4 refer to paraesophageal hernia. 10 Hiatal hernia has been recognized as an important pathophysiology of GERD and strongly correlates with BE. 10 To the best of our knowledge, only one meta-analysis, which was published in 2013, systematically reviewed the effect of hiatal hernia on BE. 11 Nevertheless, since then, numerous individual studies have been published. Furthermore, this previous meta-analysis had a major drawback that patients with endoscopically suspected BE or an irregular Z line as a control group were not explicitly excluded, thereby underestimating the effect of hiatal hernia on BE. Consequently, we have conducted an updated meta-analysis to more comprehensively and precisely determine the clinical significance of hiatal hernia on the risk of BE by combining the most recent evidence.
Methods
This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PRISMA checklist was shown in Supplemental Material.
Registration
This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO) with a registration number of CRD42022367376.
Literature search
All relevant articles reporting the prevalence of hiatal hernia in patients with and without BE were searched via PubMed, EMBASE, and Cochrane Library databases. The search items were as follows: (‘hiatal hernia’ OR ‘hiatus hernia’) AND (‘Barrett esophagus’ OR ‘Barrett’ OR ‘Barrett metaplasia’ OR ‘Barrett oesophagus’). The last search was conducted on 16 October 2022.
Selection criteria
Inclusion criteria were as follows: (1) observational (case–control or cross-sectional or cohort) studies; (2) BE should be confirmed by endoscopy with biopsies; (3) studies should compare the prevalence of hiatal hernia between participants with and without BE; (4) all participants should be older than 18 years; and (5) studies should be published in English. In case of multiple publications based on the same dataset, one publication with the most updated or inclusive data was given precedence.
Exclusion criteria were as follows: (1) duplicated studies; (2) reviews and meta-analyses; (3) case reports; (4) guidelines, consensus, or reports; (5) editorials, comments, letters, or notes; (6) experimental or animal studies; (7) studies published in the form of abstracts; (8) studies did not explore the association between hiatal hernia and BE; (9) participants included patients with endoscopically suspected BE or an irregular Z line; (10) participants were younger than 18 years old; (11) studies were not published in English; (12) overlapping participants among studies; (13) absence of relevant data; and (14) full texts could not be obtained.
Data extraction
The following data were extracted: first author, publication year, country, study design, diagnostic criteria for BE, diagnostic timing of BE, segment lengths of BE, definition of control groups, number of participants in case and control groups, and prevalence of hiatal hernia in the two groups. In addition, adjusted odds ratios (aORs) with 95% confidence intervals (CIs) and adjusted confounders were also extracted from the studies, in which multivariate regression analyses were performed to further evaluate the association of hiatal hernia with BE. Two investigators (SM and YH) independently extracted the data from the included studies, and any disagreement was resolved by discussion or consultation with a third investigator (XQ).
Study quality assessment
The quality of included case–control and cohort studies was assessed using the Newcastle–Ottawa Scale (NOS), which evaluates the quality of studies in the parts of selection (four points), comparability (two points), and exposure (three points). The maximum NOS score is 9. A score of 0–3, 4–6, and 7–9 represents low, moderate, and high quality, respectively. The quality of included cross-sectional studies was assessed using an 11-item checklist recommended by the Agency for Healthcare Research and Quality (AHRQ). An item is scored ‘1’, if the study being assessed clearly answers the question, which is marked as a ‘yes’; otherwise, it is scored ‘0’. The maximum AHRQ score is 11. A score of 0–3, 4–7, and 8–11 represents low, moderate, and high quality, respectively. Two investigators (SM and YH) independently evaluated the quality of the included studies, and any disagreement was resolved by discussion or consultation with a third investigator (XQ).
Statistical analyses
Meta-analyses were performed via Review Manager software (Version 5.4, Cochrane Collaboration, the Nordic Cochrane Centre, Copenhagen, Denmark), Stata software (Version 12.0, Stata Corp, College Station, TX, USA), and trial sequential analysis (TSA) software (Version 0.9.5.10, CTU, Centre for Clinical Intervention Research, Copenhagen, Denmark). A random-effects model was adopted to calculate the combined results and forest plots were generated for a visual display of outcome of individual studies. 12 Meta-analyses were separately performed among the studies with and without adjustment for confounders. Odds ratios (ORs) with 95% CIs were calculated for the combined estimation of unadjusted data, and aORs with 95% CIs were calculated for the combined estimates of data adjusted for confounders. The Cochrane Q test and I² statistics were conducted to assess the heterogeneity.13,14 I2 > 50% and/or p < 0.1 were considered to have statistically significant heterogeneity. TSA was conducted to assess the reliability and stability of cumulative evidence by minimizing type I error and random error.15,16 The required information size (RIS) was calculated based on a two-sided 5% risk of a type I error, 20% risk of a type II error (power of 80%), and pooled event rates in case and control groups. The trial sequential monitoring boundaries were computed using the O’Brien–Fleming approach. Subgroup analyses were planned according to the definition of controls, study design, publication year, region, sample size, diagnostic criteria for BE, diagnostic timing of BE, and adjustment for confounders to investigate the source of heterogeneity. The interaction between subgroups was assessed. Meta-regression analyses were also grouped based on the aforementioned variables. 17 Leave-one-out sensitivity analyses were employed with the removal of each study once to assess whether any single study could affect the overall result. 14 Egger test was employed to check the publication bias, and p < 0.1 indicated significant publication bias. 18
Results
Study selection
Overall, 2582 studies were searched from the PubMed, EMBASE, and Cochrane Library databases, and one study from hand-searching. Of them, 47 with a total of 131,517 participants were eligible for final review and included in this meta-analysis (Figure 1).
Figure 1.
A flowchart of study inclusion.
Study characteristics
The detailed characteristics of included studies are presented in Table 1 and Supplemental Table 1. Among them, 17 studies were case–control studies, 2 were cohort studies, and 28 were cross-sectional studies. They were published between 1985 and 2022. Sixteen studies were performed in Asia,19–34 16 in Europe,35–50 14 in America,51–64 and 1 in Oceania. 65
Table 1.
Summary of study characteristics.
| First author (year) | Country | Study design | Diagnostic criteria for BE | Diagnostic timing of BE | Length of BE | Definition of controls | Number of cases/controls | Prevalence of hiatal hernia | |
|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | ||||||||
| Farha (2022) | USA | Cohort | IM | Previously | Any | Without BE on endoscopy | 21/302 | 19/21 | 97/302 |
| Okereke (2021) | USA | Cohort | NA | Previously and newly | Any | GERD | 34/40 | 15/29 | 14/40 |
| Asreah (2021) | Iraq | Cross-sectional | IM | NA | Any | GERD and NEJ | 13/126 | 7/13 | 8/126 |
| GERD | 13/47 | 5/47 | |||||||
| NEJ | 13/79 | 3/79 | |||||||
| Alsahafi (2021) | Saudi Arabia | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 9/2787 | 4/9 | 832/2787 |
| Quach (2020) | Vietnam | Cross-sectional | CM | NA | Any | Without BE on endoscopy | 47/1900 | 8/47 | 36/1900 |
| Hadi (2020) | USA | Case–control | IM | NA | Any | Without BE on endoscopy | 107/984 | 33/107 | 280/984 |
| Alkhayyat (2020) | USA | Case–control | IM | NA | Any | Without BE on endoscopy | 18/846 | 3/18 | 22/846 |
| Chen (2019) | China | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 89/3296 | 71/89 | 1739/3296 |
| Erridge (2018) | UK | Case–control | NA | NA | Any | GERD | 2119/42,356 | 1146/2119 | 8900/42,356 |
| Bazin (2018) | France | Case–control | IM | NA | Any | GERD | 100/101 | 58/100 | 26/101 |
| Baik (2017) | USA | Case–control | IM | Previously | Any | Without BE on endoscopy | 31/27 | 23/31 | 6/27 |
| Suna (2016) | Turkey | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 18/2683 | 8/18 | 135/2683 |
| Shiota (2016) | USA | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 263/1416 | 227/263 | 890/1416 |
| Dore (2016) | Italy | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 133/5023 | 69/131 | 2206/5023 |
| Di Caro (2016) | UK | Case–control | CM | Previously and newly | Any | GERD and no-GERD | 250/224 | 141/250 | 45/224 |
| GERD | 250/28 | 9/28 | |||||||
| No-GERD | 250/196 | 36/196 | |||||||
| Sharifi (2014) | Iran | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 34/702 | 14/34 | 267/702 |
| Ren (2014) | USA | Case–control | CM | Previously | Any | GERD | 109/223 | 70/109 | 97/223 |
| Pascarenco (2014) | Romania | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 24/218 | 11/24 | 60/218 |
| LSBE | 2/218 | 1/2 | |||||||
| SSBE | 17/218 | 7/17 | |||||||
| USSBE | 5/218 | 3/5 | |||||||
| Pohl (2013) | Germany | Case–control | NA | NA | Any | GERD and no-GERD | 162/301 | 76/162 | 79/301 |
| GERD | 162/188 | 54/188 | |||||||
| No-GERD | 162/113 | 25/113 | |||||||
| Nason (2013) | USA | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 33/245 | 25/33 | 129/245 |
| Katsinelos (2013) | Greece | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 75/1915 | 16/75 | 180/1915 |
| Yin (2012) | China | Cross-sectional | IM | NA | Any | GERD | 32/496 | 10/32 | 40/496 |
| Mathew (2011) | India | Cross-sectional | CM | NA | Any | GERD | 46/232 | 11/46 | 14/232 |
| Jonaitis (2011) | Lithuania | Cross-sectional | IM | NA | Any | GERD | 33/160 | 33/33 | 142/160 |
| Xiong (2010) | China | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 21/2001 | 1/21 | 28/2001 |
| Kuo (2010) | China | Cross-sectional | IM | NA | Any | GERD | 13/331 | 7/13 | 31/331 |
| Peng (2009) | China | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 27/2553 | 3/27 | 43/2553 |
| Odemis (2009) | Turkey | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 12/988 | 7/12 | 43/988 |
| Lord (2009) | USA | Case–control | IM | NA | Any | Without BE on endoscopy | 44/116 | 37/44 | 70/116 |
| Park (2009) | Korea | Cross-sectional | IM | NA | Any | Without BE on endoscopy | 215/23,350 | 28/215 | 619/23,350 |
| Ringhofer (2008) | Austria | Cross-sectional | IM | Newly | Any | GERD | 19/83 | 11/19 | 14/83 |
| Moons (2008) | Netherlands | Case–control | IM | Previously and newly | Any | GERD | 255/247 | 217/255 | 161/247 |
| Tseng (2008) | China | Cross-sectional | CM | NA | Any | GERD and no-GERD | 12/19,776 | 1/12 | 157/19,776 |
| GERD | 12/3129 | 31/3129 | |||||||
| No-GERD | 12/16,647 | 126/16,647 | |||||||
| Lee (2008) | China | Case–control | IM | NA | Any | GERD | 21/28 | 15/21 | 16/28 |
| Koek (2008) | Belgium | Cross-sectional | IM | NA | Any | GERD | 30/392 | 14/30 | 141/392 |
| Sgouros (2007) | Greece | Case–control | IM | Newly | Any | GERD and no-GERD | 17/846 | 15/17 | 458/846 |
| GERD | 17/597 | 405/597 | |||||||
| No-GERD | 17/249 | 53/249 | |||||||
| Rajendra (2007) | Malaysia | Case–control | CM | Previously | Any | GERD and no-GERD | 55/133 | 29/55 | 11/133 |
| LSBE | 30/133 | 22/30 | |||||||
| SSBE | 25/133 | 7/25 | |||||||
| Any | GERD | 55/80 | 29/55 | 10/80 | |||||
| LSBE | 30/80 | 22/30 | |||||||
| SSBE | 25/80 | 7/25 | |||||||
| Any | No-GERD | 55/53 | 29/55 | 1/53 | |||||
| LSBE | 30/53 | 22/30 | |||||||
| SSBE | 25/53 | 7/25 | |||||||
| Veldhuyzen van Zanten (2006) | Canada | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 25/1015 | 7/25 | 228/1015 |
| Toruner (2004) | Turkey | Cross-sectional | IM | Newly | Any | Without BE on endoscopy | 29/366 | 19/29 | 129/366 |
| Rajendra (2004) | Malaysia | Cross-sectional | IM | NA | Any | GERD and no-GERD | 123/1862 | 33/123 | 123/1862 |
| GERD | 123/121 | 17/121 | |||||||
| No-GERD | 123/1741 | 106/1741 | |||||||
| Nasseri-Moghaddam (2003) | Iran | Cross-sectional | CM | Newly | Any | GERD | 68/139 | 53/68 | 98/139 |
| LSBE | 10/139 | 8/10 | |||||||
| SSBE | 58/139 | 45/58 | |||||||
| Conio (2002) | Italy | Case–control | IM | Newly | Any | GERD and no-GERD | 149/451 | 83/147 | 85/451 |
| GERD | 149/143 | 64/143 | |||||||
| No-GERD | 149/308 | 21/308 | |||||||
| Campos (2001) | USA | Case–control | IM | NA | Any | GERD | 174/328 | 150/174 | 183/328 |
| LSBE | 107/328 | 101/107 | |||||||
| SSBE | 67/328 | 49/67 | |||||||
| Avidan (2001) | USA | Case–control | IM | NA | Any | NEJ | 1016/3047 | 588/1016 | 803/3047 |
| LSBE | 366/3047 | 230/366 | |||||||
| SSBE | 650/3047 | 358/650 | |||||||
| Cameron (1999) | USA | Case–control | IM | Previously | Any | GERD and no-GERD | 64/103 | 57/64 | 43/103 |
| LSBE | 46/103 | 44/46 | |||||||
| SSBE | 18/103 | 13/18 | |||||||
| Any | GERD | 64/31 | 57/64 | 22/31 | |||||
| LSBE | 46/31 | 44/46 | |||||||
| SSBE | 18/31 | 13/18 | |||||||
| Any | No-GERD | 64/72 | 57/64 | 21/72 | |||||
| LSBE | 46/72 | 44/46 | |||||||
| SSBE | 18/72 | 13/18 | |||||||
| Byrne (1999) | UK | Cross-sectional | CM | Previously | Any | Without BE on endoscopy | 23/194 | 17/23 | 59/194 |
| LSBE | 8/194 | 8/8 | |||||||
| SSBE | 15/194 | 9/15 | |||||||
| Sarr (1985) | USA | Cross-sectional | CM | NA | Any | Without BE on endoscopy | 44/318 | 31/44 | 152/318 |
BE, Barrett’s esophagus; CM, columnar metaplasia; GERD, gastroesophageal reflux disease; IM, intestinal metaplasia; LSBE, long-segment BE; NEJ, normal esophagogastric junction; SSBE, short-segment BE; USSBE, ultrashort-segment BE.
Study quality
Among the case–control and cohort studies, 15 and 4 were of moderate and high quality, respectively (Supplemental Table 2). Among the cross-sectional studies, 24 and 4 were of moderate and high quality, respectively (Supplemental Table 3).
Hiatal hernia and any length BE
Based on the unadjusted data from 17 case–control, 2 cohort, and 28 cross-sectional studies, the meta-analysis demonstrated a significantly higher prevalence of hiatal hernia in patients with BE than those without (OR = 3.91, 95% CI = 3.31–4.62, p < 0.001). The heterogeneity was statistically significant (I² = 77%; p < 0.001) (Figure 2). According to TSA, the cumulative Z-curves crossed the conventional test boundary and TSA boundary, and the total sample size surpassed the RIS (n = 1022) as well, indicating that there was enough evidence to conclude a significant association of hiatal hernia with an increased risk of any length BE (Supplemental Figure 1). Results of subgroup analyses were shown in Table 2. Such a statistically significant association between them disappeared in the subgroup analyses of cohort studies (OR = 5.92, 95% CI = 0.58–60.36, p = 0.13), but remained in others. The interaction between subgroups was only significant in the subgroup analysis according to the definition of controls (p = 0.005), but not in others. A high level of heterogeneity was observed between studies in all subgroups. Meta-regression analyses indicated that the definition of controls (p = 0.014) might be a potential contributor to heterogeneity (Supplemental Table 4). Leave-one-out sensitivity analyses showed that no single study influenced the overall result (Supplemental Table 5). Egger test did not show any significant publication bias (p = 0.984).
Figure 2.
Forest plots showing the association of hiatal hernia with any length BE based on unadjusted data.
BE, Barrett’s esophagus.
Table 2.
Results of subgroup analyses regarding the association of hiatal hernia with BE in studies unadjusted for confounders.
| Groups | Any length BE | LSBE | SSBE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | Heterogeneity | P interaction | OR (95% CI) | Heterogeneity | P interaction | OR (95% CI) | Heterogeneity | P interaction | ||||
| I² (%) | p Value | I² (%) | p Value | I² (%) | p Value | |||||||
| Total | 3.91 (3.31–4.62, p < 0.001) | 77 | <0.001 | 10.01 (4.16–24.06, p < 0.001) | 78 | <0.001 | 2.76 (2.05–3.71, p < 0.001) | 30 | 0.201 | |||
| Definition of controls | 0.005 | <0.001 | 0.008 | |||||||||
| Without BE on endoscopy | 3.82 (2.71–5.37, p < 0.001) | 80 | <0.001 | 9.90 (0.62–158.95, p = 0.11) | 48 | 0.170 | 2.47 (1.18–5.15, p = 0.02) | 0 | 0.410 | |||
| GERD | 3.27 (2.59–4.11, p < 0.001) | 67 | <0.001 | 9.23 (3.71–22.99, p < 0.001) | 55 | 0.080 | 1.84 (1.24–2.74, p = 0.003) | 0 | 0.590 | |||
| No-GERD | 9.92 (5.53–17.79, p < 0.001) | 79 | <0.001 | 74.05 (21.63–253.55.99, p < 0.001) | 0 | 0.460 | 8.16 (2.96–22.52, p < 0.001) | 0 | 0.350 | |||
| NEJ | 9.08 (1.26–65.51, p = 0.03) | 84 | 0.010 | 4.73 (3.77–5.93, p < 0.001) | – | – | 3.43 (2.88–4.08, p < 0.001) | – | – | |||
| Study design | 0.940 | 0.300 | 0.040 | |||||||||
| Case–control | 3.93 (3.18–4.87, p < 0.001) | 78 | <0.001 | 14.00 (4.75–41.27, p < 0.001) | 87 | <0.001 | 3.33 (2.83–3.92, p < 0.001) | 0 | 0.480 | |||
| Cross-sectional | 3.98 (2.97–5.33, p < 0.001) | 76 | <0.001 | 4.39 (0.65–29.80, p = 0.13) | 49 | 0.140 | 1.88 (1.12–3.14, p = 0.02) | 0 | 0.420 | |||
| Cohort | 5.92 (0.58–60.36, p = 0.13) | 86 | 0.009 | – | – | – | – | – | – | |||
| Publication year | 0.360 | 0.340 | 0.420 | |||||||||
| After 2010 | 3.69 (2.85–4.78, p < 0.001) | 81 | <0.001 | 2.63 (0.16–42.77, p = 0.50) | – | – | 1.84 (0.67–5.06, p = 0.24) | – | – | |||
| Before 2010 | 4.34 (3.42–5.53, p < 0.001) | 67 | <0.001 | 11.10 (4.36–28.23, p < 0.001) | 81 | <0.001 | 2.84 (2.08–3.89, p < 0.001) | 33 | 0.190 | |||
| Region | 0.490 | 0.980 | 0.690 | |||||||||
| Asia | 4.65 (3.17–6.83, p < 0.001) | 71 | <0.001 | 7.62 (0.42–138.44, p = 0.17) | 89 | 0.002 | 2.32 (0.80–6.75, p = 0.12) | 64 | 0.090 | |||
| Europe | 3.85 (2.89–5.15, p < 0.001) | 81 | <0.001 | 9.90 (0.62–158.95, p = 0.11) | 48 | 0.170 | 2.47 (1.18–5.15, p = 0.02) | 0 | 0.410 | |||
| America | 3.44 (2.49–4.75, p < 0.001) | 77 | <0.001 | 10.56 (3.52–31.65, p < 0.001) | 83 | 0.003 | 3.21 (2.54–4.06, p < 0.001) | 11 | 0.320 | |||
| Oceania | 6.78 (2.31–19.89, p < 0.001) | – | – | – | – | – | – | – | – | |||
| Sample size | 0.740 | 0.050 | 0.040 | |||||||||
| >500 | 3.84 (3.08–4.79, p < 0.001) | 83 | <0.001 | 4.73 (3.77–5.93, p < 0.001) | – | – | 3.43 (2.88–4.08, p < 0.001) | – | – | |||
| <500 | 4.08 (3.08–5.42, p < 0.001) | 65 | <0.001 | 12.61 (4.90–32.48, p < 0.001) | 59 | 0.030 | 2.29 (1.62–3.23, p < 0.001) | 0 | 0.500 | |||
| Diagnostic criteria for BE | 0.630 | 0.840 | 0.610 | |||||||||
| IM | 4.00 (3.19–5.01, p < 0.001) | 77 | <0.001 | 9.10 (3.41–24.34, p < 0.001) | 75 | 0.008 | 3.07 (2.38–3.96, p < 0.001) | 14 | 0.320 | |||
| CM | 4.55 (2.82–7.35, p < 0.001) | 75 | <0.001 | 11.58 (1.35–98.99, p = 0.03) | 79 | 0.008 | 2.52 (1.23–5.15, p = 0.01) | 43 | 0.170 | |||
| Diagnostic timing of BE | 0.190 | 0.005 | 0.100 | |||||||||
| Newly diagnosed | 4.12 (2.25–7.55, p = 0.002) | 86 | <0.001 | 1.67 (0.34–8.22, p = 0.53) | – | – | 1.45 (0.71–2.97, p = 0.31) | – | – | |||
| Previously diagnosed | 7.97 (3.66–17.35, p < 0.001) | 78 | <0.001 | 32.22 (8.71–119.20, p < 0.001) | 0 | 0.890 | 3.53 (1.63–7.62, p = 0.001) | 0 | 0.940 | |||
Note: Bold italic font indicates statistically significant.BE, Barrett’s esophagus; CI, confidence intervals; CM, columnar metaplasia; GERD, gastroesophageal reflux disease; IM, intestinal metaplasia; LSBE, long-segment BE; NEJ, normal esophagogastric junction; OR, odds ratio; SSBE, short-segment BE.
Based on the adjusted data from six case–control and eight cross-sectional studies, the meta-analysis demonstrated a significantly higher prevalence of hiatal hernia in patients with BE than those without (aOR = 3.26, 95% CI = 2.44–4.35, p < 0.001). The heterogeneity was statistically significant (I² = 65%; p < 0.001) (Figure 3). TSA could not be carried out owing to the inability to extract the prevalence rate in multivariate regression models. Results of subgroup analyses were shown in Table 3. Such a statistically significant association between them disappeared in the subgroup analyses of studies performed in America (OR = 1.98, 95% CI = 0.90–4.39, p = 0.09), but remained in others. The interaction between all subgroups was not significant. A high level of heterogeneity was observed between studies in all subgroups. Meta-regression analyses did not identify any source of heterogeneity (Supplemental Table 6). The heterogeneity significantly decreased after omitting the study by Hadi et al. 54 (I² = 0%; p = 0.44), indicating that this study might be a potential contributor to heterogeneity (Supplemental Table 7). Egger test did not show any significant publication bias (p = 0.416).
Figure 3.
Forest plots showing the association of hiatal hernia with any length BE based on adjusted data.
BE, Barrett’s esophagus.
Table 3.
Results of subgroup analyses regarding the association of hiatal hernia with BE in studies adjusted for confounders.
| Groups | Any length BE | |||
|---|---|---|---|---|
| aOR (95% CI) | Heterogeneity | P interaction | ||
| I² (%) | p Value | |||
| Total | 3.26 (2.44–4.35, p < 0.001) | 65 | <0.001 | |
| Definition of controls | 0.720 | |||
| Without BE on endoscopy | 3.06 (1.64–5.71, p < 0.001) | 80 | <0.001 | |
| GERD | 3.29 (2.34–4.61, p < 0.001) | 0 | 0.430 | |
| No-GERD | 3.90 (2.50–6.08, p < 0.001) | – | – | |
| NEJ | 2.96 (2.43–3.61, p < 0.001) | – | – | |
| Study design | 0.210 | |||
| Case–control | 2.82 (1.80–4.43, p < 0.001) | 81 | <0.001 | |
| Cross-sectional | 3.97 (3.00–5.25, p < 0.001) | 0 | 0.650 | |
| Publication year | 0.990 | |||
| After 2010 | 3.32 (1.91–5.77, p < 0.001) | 72 | <0.001 | |
| Before 2010 | 3.30 (2.66–4.10, p < 0.001) | 26 | 0.250 | |
| Region | 0.230 | |||
| Asia | 4.16 (3.09–5.59, p < 0.001) | 0 | 0.640 | |
| Europe | 3.60 (2.52–5.15, p < 0.001) | 24 | 0.270 | |
| America | 1.98 (0.90–4.39, p = 0.09) | 89 | <0.001 | |
| Sample size | 0.270 | |||
| >500 | 3.09 (2.24–4.26, p < 0.001) | 71 | <0.001 | |
| <500 | 4.44 (2.53–7.80, p < 0.001) | 0 | 0.670 | |
| Diagnostic criteria for BE | 0.280 | |||
| IM | 3.00 (2.22–4.07, p < 0.001) | 68 | <0.001 | |
| CM | 4.98 (2.11–11.71, p < 0.001) | 42 | 0.190 | |
| Confounders adjusted | 0.750 | |||
| Full adjusted a | 3.64 (1.58–8.42, p = 0.002) | 82 | <0.001 | |
| Not full adjusted | 3.17 (2.73–3.67, p < 0.001) | 0 | 0.600 | |
Full adjusted: at least age, gender, reflux symptoms, smoking, BMI, and/or waist circumference were adjusted.
aOR, adjusted odds ratio; BE, Barrett’s esophagus; CI, confidence intervals; CM, columnar metaplasia; GERD, gastroesophageal reflux disease; IM, intestinal metaplasia; NEJ, normal esophagogastric junction.
Hiatal hernia and long-segment BE (LSBE)
Seven studies explored the association between hiatal hernia and LSBE. There was a significantly higher prevalence of hiatal hernia in patients with LSBE than those without BE (OR = 10.01, 95% CI = 4.16–24.06, p < 0.001). The heterogeneity was statistically significant (I² = 78%; p < 0.001) (Figure 4). According to TSA, the cumulative Z-curves crossed the conventional test boundary and TSA boundary, and the total sample size surpassed the RIS (n = 722) as well, indicating that there was enough evidence to conclude a significant association of hiatal hernia with an increased risk of LSBE (Supplemental Figure 2). Such a statistically significant association between them disappeared in the subgroup analyses of cross-sectional studies (OR = 4.39, 95% CI = 0.65–29.80, p = 0.13), those regarding patients without BE on endoscopy as the control group (OR = 9.90, 95% CI = 0.62–158.95, p = 0.11), those published after 2010 (OR = 2.63, 95% CI = 0.16–42.77, p = 0.50), those performed in Europe (OR = 9.90, 95% CI = 0.62–158.95, p = 0.11), and those which included newly diagnosed BE (OR = 1.67, 95% CI = 0.34–8.22, p = 0.53), but remained in others. The interaction between subgroups was statistically significant in the subgroup analyses according to the definition of controls (p < 0.001) and diagnostic timing of BE (p = 0.005), but not in others. Among the subgroup analyses, the heterogeneity remains substantial (Table 2). Meta-regression analyses did not find any source of heterogeneity (Supplemental Table 4). Leave-one-out sensitivity analyses showed that no single study influenced the overall result (Supplemental Table 8). Egger test did not show any significant publication bias (p = 0.210).
Figure 4.
Forest plots showing the association of hiatal hernia with LSBE.
LSBE, long-segment Barrett’s esophagus.
Hiatal hernia and short-segment BE (SSBE)
Seven studies explored the association between hiatal hernia and SSBE. There was a significantly higher prevalence of hiatal hernia in patients with SSBE than those without BE (OR = 2.76, 95% CI = 2.05–3.71, p < 0.001). The heterogeneity was not significant (I² = 30%; p = 0.201) (Figure 5). According to TSA, the cumulative Z-curves crossed the conventional test boundary and TSA boundary, and the total sample size surpassed the RIS (n = 583) as well, indicating that there was enough evidence to conclude a significant association of hiatal hernia with an increased risk of SSBE (Supplemental Figure 3). Such a statistically significant association between them disappeared in the subgroup analyses of studies published after 2010 (OR = 1.84, 95% CI = 0.67–5.06, p = 0.24), those performed in Asia (OR = 2.32, 95% CI = 0.80–6.75, p = 0.12), and those which included newly diagnosed BE (OR = 1.45, 95% CI = 0.71–2.97, p = 0.31), but remained in others. The interaction between subgroups was statistically significant in the subgroup analyses according to the definition of controls (p = 0.008), study design (p = 0.040), and sample size (p = 0.040), but not in others (Table 2). Egger test did not show any significant publication bias (p = 0.261).
Figure 5.
Forest plots showing the association of hiatal hernia with SSBE.
SSBE, short-segment Barrett’s esophagus.
Discussion
The current practice guidelines do not consider the presence of hiatal hernia as a risk factor for BE1, 5–8. Our meta-analysis comprehensively searched relevant studies to explore the association of hiatal hernia with BE. We found that the presence of hiatal hernia was associated with a 3.91-fold increased risk for any length BE, a 10.01-fold increased risk for LSBE, and a 2.76-fold increased risk for SSBE. This association between hiatal hernia and BE remained significant even after adjustment for potential confounders, suggesting that hiatal hernia should be a significant risk factor for BE.
Currently, only one previous meta-analysis regarding the association between hiatal hernia and BE was published. 11 By comparison, our current meta-analysis had some advantages. First, the final search date was updated to retrieve a more comprehensive collection of eligible studies. Second, TSA was performed by minimizing random errors to evaluate the reliability and conclusiveness of conventional meta-analyses, which has not been conducted in the previous meta-analysis yet. Third, more subgroup analyses were carried out to further explore the association between hiatal hernia and BE according to the seven prespecified baseline subgroups, and tests of interaction were also performed to establish whether the subgroups differed significantly from one another, which has not been performed in the previous meta-analysis yet. Fourth, meta-regression analyses for variables between studies were used to explore the potential causes of heterogeneity in our meta-analysis, but have not been done in the previous meta-analysis yet. Fifth, it is commendable that the selection criteria in our meta-analysis were more rigorous and plausible. Specifically, the participants included in control groups should not have endoscopically suspected BE or an irregular Z line. This consideration was very essential to avert the influences of these potential confounding factors on the reliability of our findings. Such selection criteria have not been employed by the previous meta-analysis, resulting in the inclusion of five ineligible studies.66–70
The pathogenesis of BE is primarily attributed to the impairment of the anti-reflux barrier, which leads to the exposure of esophageal mucosa to gastric and bile acids, resulting in damage to esophageal mucosa.71,72 The causal role of hiatal hernia in an increased risk of BE may be explained by increased acid reflux due to the incompetence of gastroesophageal junction (GEJ), delay of esophageal acid clearance, and increased frequency of transient lower esophageal sphincter relaxations (tLESRs).
The first mechanism should be impaired GEJ function, as follows: (1) Gastroesophageal flap valve (GEFV), an important part of anti-reflux barrier, is a 180° musculomucosal fold formed by the intraluminal extension of the angle of His, which functions as a one-way valve. 73 Loss of the angle of His caused by hiatal hernia can impair the function of GEFV, and then promote reflux. 74 (2) Hiatal hernia may displace the lower esophageal sphincter (LES) proximally, and resting LES pressure can decrease with increasing displacement, thereby promoting reflux. 75 (3) A large hiatal hernia may widen the diaphragmatic hiatus, which weakens the ability of the crural diaphragm to function as an external sphincter, leading to the occurrence of reflux. 76
The second is delayed esophageal acid clearance, as follows: (1) Gastric and bile acids may be trapped in hiatal hernia sac that acts as a reservoir, and then reflux proximally into the esophagus during a swallow-induced LES relaxation.77,78 This sequence can be repeated, resulting in significantly delayed esophageal acid clearance. 76 (2) A large hiatal hernia may decrease the peristaltic wave amplitude and frequency in distal esophagus which is associated with delayed esophageal acid clearance.79,80
The third is tLESRs, a physiological phenomenon during digestion mediated via vagal pathways. 81 The presence of hiatal hernia is associated with a reduced threshold for eliciting tLESRs, increasing the frequency of tLESRs, which finally results in prolongation of esophageal acid exposure. 82
In addition, esophageal injury caused by BE may lead to esophageal shortening and fibrosis, which may increase the size of hiatal hernia and worsen existing anti-reflux dysfunction,83,84 and then further aggravates reflux.
We also found a more significant association of hiatal hernia with LSBE compared with SSBE. It seems obvious that LSBE has a greater esophageal acid exposure than SSBE.85,86 This phenomenon may be attributed to the difference in their pathogenesis where LSBE may have a significantly lower LES pressure and a worse function of esophageal peristalsis primarily caused by hiatal hernia than SSBE.87–89 Hence, LSBE may be more affected by acid reflux attributed to hiatal hernia and demonstrate a stronger association with hiatal hernia.
Our meta-analysis had several limitations. First, a majority of the included studies were retrospective, which inevitably leads to selection bias and recall bias, and a cause–effect relationship between hiatal hernia and BE could not be established due to the inherent weakness of retrospective study design. Second, the heterogeneity among studies regarding the association of hiatal hernia with LSBE was significant, in spite of leave-one-out sensitivity analyses and meta-regression analyses. Third, only some of included studies adjusted the confounders in multivariate regression analyses, and the confounders adjusted were inconsistent among them. Fourth, the association of hiatal hernia with BE was not the primary objective in most of the included studies. The diagnosis of hiatal hernia was based on endoscopy only, which may result in missed diagnoses of some small hiatal hernia or misdiagnosis of hiatal hernia caused by episodes of retching during endoscopy, 10 thereby underestimating or overestimating the effect of hiatal hernia on BE, respectively. Fifth, the information regarding the size of hiatal hernia was limited. In detail, only two studies reported the length of hiatal hernia,58,62 and only three studies reported the number of different sized hiatal hernia grouped by different classification criteria in patients with and without BE.51,55,56 Therefore, the effect of the size of hiatal hernia on BE could not be explored by subgroup analyses. Sixth, the absence of detailed information on the type of hiatal hernia prevented from further analysis regarding the association between subtypes of hiatal hernia and BE. Seventh, our meta-regression analyses indicated that the definition of control group might be a potential contributor to heterogeneity. Specifically, as shown in Table 2, our subgroup analyses demonstrated that the association of hiatal hernia with BE was weaker in the control group of GERD than the control group of non-GERD. These findings suggested that the association of hiatal hernia with BE might be dependent upon the presence of GERD. Indeed, a recent meta-analysis by Eusebi et al. 90 also indicated that hiatal hernia should be the strongest risk factor for the presence of BE in patients with GERD. Therefore, it is unclear about whether hiatal hernia is indirectly associated with BE by increasing the risk of GERD or directly involved in the development of BE in GERD patients.
Conclusion
The current evidence supports a close relationship between hiatal hernia and an increased risk of BE, which remains after adjusting for confounders. Additionally, hiatal hernia seems to correlate more strongly with LSBE compared with SSBE. More large-scale prospective cohort studies are required to confirm our findings in future.
Supplemental Material
Supplemental material, sj-docx-1-tag-10.1177_17562848231219234 for Association between hiatal hernia and Barrett’s esophagus: an updated meta-analysis with trial sequential analysis by Shaoze Ma, Zhenhua Tong, Yong He, Yiyan Zhang, Xiaozhong Guo and Xingshun Qi in Therapeutic Advances in Gastroenterology
Acknowledgments
None.
Footnotes
ORCID iD: Xingshun Qi
https://orcid.org/0000-0002-9448-6739
Supplemental material: Supplemental material for this article is available online.
Contributor Information
Shaoze Ma, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China; Graduate School, Dalian Medical University, Dalian, China.
Zhenhua Tong, Section of Medical Service, General Hospital of Northern Theater Command, Shenyang, China.
Yong He, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China; Graduate School, Shenyang Pharmaceutical University, Shenyang, China.
Yiyan Zhang, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China; Graduate School, China Medical University, Shenyang, China.
Xiaozhong Guo, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, Liaoning 110840, China.
Xingshun Qi, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, Liaoning 110840, China.
Declarations
Ethics approval and consent to participate: Not applicable.
Consent for publication: All authors have made an intellectual contribution to the manuscript and approved the submission.
Author contributions: Shaoze Ma: Data curation; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.
Zhenhua Tong: Formal analysis; Methodology; Writing – review & editing.
Yong He: Data curation; Formal analysis; Methodology; Writing – review & editing.
Yiyan Zhang: Data curation; Formal analysis; Methodology; Writing – review & editing.
Xiaozhong Guo: Formal analysis; Methodology; Supervision; Writing – review & editing.
Xingshun Qi: Conceptualization; Formal analysis; Methodology; Supervision; Writing – original draft; Writing – review & editing.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
The authors declare that there is no conflict of interest.
Availability of data and materials: Data sharing is not applicable to this article as no new data were created in this study.
References
- 1. Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30–50; quiz 51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012; 61: 970–976. [DOI] [PubMed] [Google Scholar]
- 3. Cook MB, Coburn SB, Lam JR, et al. Cancer incidence and mortality risks in a large US Barrett’s oesophagus cohort. Gut 2018; 67: 418–529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol 2021; 18: 432–443. [DOI] [PubMed] [Google Scholar]
- 5. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7–42. [DOI] [PubMed] [Google Scholar]
- 6. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017; 49: 191–198. [DOI] [PubMed] [Google Scholar]
- 7. Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90: 335–359.e2. [DOI] [PubMed] [Google Scholar]
- 8. Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut 2016; 65: 1402–1415. [DOI] [PubMed] [Google Scholar]
- 9. Kohn GP, Price RR, DeMeester SR, et al. Guidelines for the management of hiatal hernia. Surg Endosc 2013; 27: 4409–4428. [DOI] [PubMed] [Google Scholar]
- 10. Sfara A, Dumitrascu DL. The management of hiatal hernia: an update on diagnosis and treatment. Med Pharm Rep 2019; 92: 321–325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Andrici J, Tio M, Cox MR, et al. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol 2013; 28: 415–431. [DOI] [PubMed] [Google Scholar]
- 12. Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010; 1: 97–111. [DOI] [PubMed] [Google Scholar]
- 13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558. [DOI] [PubMed] [Google Scholar]
- 14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64–75. [DOI] [PubMed] [Google Scholar]
- 16. Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 2009; 38: 276–286. [DOI] [PubMed] [Google Scholar]
- 17. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559–1573. [DOI] [PubMed] [Google Scholar]
- 18. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Alsahafi M, Mimish H, Salem F, et al. The prevalence of Barrett’s esophagus among a Saudi Arabian population. Dig Dis Sci 2021; 66: 2311–2316. [DOI] [PubMed] [Google Scholar]
- 20. Asreah RH, Abdullhameed A. Risk factors of erosive esophagitis and Barrett’s esophagus in patients with reflux symptoms. Med J Islam Repub Iran 2021; 35: 75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Quach DT, Pham QTT, Tran TLT, et al. Prevalence, clinical characteristics, and risk factors of Barrett esophagus in Vietnamese patients with upper gastrointestinal symptoms. Medicine (Baltimore) 2020; 99: e21791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Chen YH, Yu HC, Lin KH, et al. Prevalence and risk factors for Barrett’s esophagus in Taiwan. World J Gastroenterol 2019; 25: 3231–3241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Sharifi A, Dowlatshahi S, Moradi Tabriz H, et al. The prevalence, risk factors, and clinical correlates of erosive esophagitis and Barrett’s esophagus in Iranian patients with reflux symptoms. Gastroenterol Res Pract 2014; 2014: 696294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Yin C, Zhang J, Gao M, et al. Epidemiological investigation of Barrett’s esophagus in patients with gastroesophageal reflux disease in Northwest China. J Med Coll PLA 2012; 27: 187–197. [Google Scholar]
- 25. Mathew P, Joshi AS, Shukla A, et al. Risk factors for Barrett’s esophagus in Indian patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 2011; 26: 1151–1156. [DOI] [PubMed] [Google Scholar]
- 26. Kuo CJ, Lin CH, Liu NJ, et al. Frequency and risk factors for Barrett’s esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci 2010; 55: 1337–1343. [DOI] [PubMed] [Google Scholar]
- 27. Xiong LS, Cui Y, Wang JP, et al. Prevalence and risk factors of Barrett’s esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. J Dig Dis 2010; 11: 83–87. [DOI] [PubMed] [Google Scholar]
- 28. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett’s esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol 2009; 43: 907–914. [DOI] [PubMed] [Google Scholar]
- 29. Peng S, Cui Y, Xiao YL, et al. Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy 2009; 41: 1011–1017. [DOI] [PubMed] [Google Scholar]
- 30. Lee TY, Lien HC, Chang CS, et al. Barrett’s esophagus and severe reflux esophagitis share common pathophysiological characteristics among Chinese in Taiwan. Intern Med 2008; 47: 1767–1773. [DOI] [PubMed] [Google Scholar]
- 31. Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population. J Clin Gastroenterol 2008; 42: 1074–1079. [DOI] [PubMed] [Google Scholar]
- 32. Rajendra S, Ackroyd R, Robertson IK, et al. Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter 2007; 12: 177–183. [DOI] [PubMed] [Google Scholar]
- 33. Rajendra S, Kutty K, Karim N. Ethnic differences in the prevalence of endoscopic esophagitis and Barrett’s esophagus: the long and short of it all. Dig Dis Sci 2004; 49: 237–242. [DOI] [PubMed] [Google Scholar]
- 34. Nasseri-Moghaddam S, Malekzadeh R, Sotoudeh M, et al. Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol 2003; 18: 315–321. [DOI] [PubMed] [Google Scholar]
- 35. Bazin C, Benezech A, Alessandrini M, et al. Esophageal motor disorders are a strong and independant associated factor of Barrett’s esophagus. J Neurogastroenterol Motil 2018; 24: 216–225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Erridge S, Moussa OM, Ziprin P, et al. Risk of GERD-related disorders in obese patients on PPI therapy: a population analysis. Obes Surg 2018; 28: 2796–2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Di Caro S, Cheung WH, Fini L, et al. Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer. Eur J Gastroenterol Hepatol 2016; 28: 251–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Dore MP, Pes GM, Bassotti G, et al. Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett’s esophagus in Northern Sardinia. Scand J Gastroenterol 2016; 51: 1281–1287. [DOI] [PubMed] [Google Scholar]
- 39. Suna N, Parlak E, Kuzu UB, et al. The prevalence of Barrett esophagus diagnosed in the second endoscopy: a retrospective, observational study at a tertiary center. Medicine (Baltimore) 2016; 95: e3313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Pascarenco OD, Boeriu A, Mocan S, et al. Barrett’s esophagus and intestinal metaplasia of gastric cardia: prevalence, clinical, endoscopic and histological features. J Gastrointestin Liver Dis 2014; 23: 19–25. [PubMed] [Google Scholar]
- 41. Katsinelos P, Lazaraki G, Kountouras J, et al. Prevalence of Barrett’s esophagus in Northern Greece: a prospective study (Barrett’s esophagus). Hippokratia 2013; 17: 27–33. [PMC free article] [PubMed] [Google Scholar]
- 42. Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013; 108: 200–207. [DOI] [PubMed] [Google Scholar]
- 43. Jonaitis L, Kriukas D, Kiudelis G, et al. Risk factors for erosive esophagitis and Barrett’s esophagus in a high Helicobacter pylori prevalence area. Medicina (Kaunas), 2011; 47: 434–439. [PubMed] [Google Scholar]
- 44. Odemiş B, Ciçek B, Zengin NI, et al. Barrett’s esophagus and endoscopically assessed esophagogastric junction integrity in 1000 consecutive Turkish patients undergoing endoscopy: a prospective study. Dis Esophagus 2009; 22: 649–655. [DOI] [PubMed] [Google Scholar]
- 45. Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett’s oesophagus. Gut 2008; 57: 1056–1064. [DOI] [PubMed] [Google Scholar]
- 46. Moons LM, Kusters JG, van Delft JH, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis 2008; 29: 926–931. [DOI] [PubMed] [Google Scholar]
- 47. Sgouros SN, Mpakos D, Rodias M, et al. Prevalence and axial length of hiatus hernia in patients, with nonerosive reflux disease: a prospective study. J Clin Gastroenterol 2007; 41: 814–818. [DOI] [PubMed] [Google Scholar]
- 48. Toruner M, Soykan I, Ensari A, et al. Barrett’s esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol 2004; 19: 535–540. [DOI] [PubMed] [Google Scholar]
- 49. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett’s esophagus: a case–control study. Int J Cancer 2002; 97: 225–229. [DOI] [PubMed] [Google Scholar]
- 50. Byrne JP, Bhatnagar S, Hamid B, et al. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol 1999; 94: 98–103. [DOI] [PubMed] [Google Scholar]
- 51. Farha N, Lyu R, Liska D, et al. Prevalence and risk factors of Barrett’s esophagus in lynch syndrome. Fam Cancer 2022; 22: 55–60. [DOI] [PubMed] [Google Scholar]
- 52. Okereke IC, Miller AL, Jupiter DC, et al. Microbiota detection patterns correlate with presence and severity of Barrett’s esophagus. Front Cell Infect Microbiol 2021; 11: 555072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Alkhayyat M, Sanghi V, Qapaja T, et al. Pyloroplasty and the risk of Barrett’s esophagus in patients with gastroparesis. Dis Esophagus 2020; 33: doaa049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Hadi YB, Khan AA, Naqvi SFZ, et al. Independent association of obstructive sleep apnea with Barrett’s esophagus. J Gastroenterol Hepatol 2020; 35: 408–411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Baik D, Sheng J, Schlaffer K, et al. Abdominal diameter index is a stronger predictor of prevalent Barrett’s esophagus than BMI or waist-to-hip ratio. Dis Esophagus 2017; 30: 1–6. [DOI] [PubMed] [Google Scholar]
- 56. Shiota S, El-Serag HB, Thrift AP. Premature birth and large for gestational age are associated with risk of Barrett’s esophagus in adults. Dig Dis Sci 2016; 61: 1139–1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Ren D, Zheng G, Bream S, et al. Single nucleotide polymorphisms of caudal type homeobox 1 and 2 are associated with Barrett’s esophagus. Dig Dis Sci 2014; 59: 57–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Nason KS, Murphy T, Schindler J, et al. A cross-sectional analysis of the prevalence of Barrett esophagus in otolaryngology patients with laryngeal symptoms. J Clin Gastroenterol 2013; 47: 762–768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Lord RV, DeMeester SR, Peters JH, et al. Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg 2009; 13: 602–610. [DOI] [PubMed] [Google Scholar]
- 60. Veldhuyzen van Zanten SJ, Thomson AB, Barkun AN, et al. The prevalence of Barrett’s oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. Aliment Pharmacol Ther 2006; 23: 595–599. [DOI] [PubMed] [Google Scholar]
- 61. Avidan B, Sonnenberg A, Schnell TG, et al. Gastric surgery is not a risk for Barrett’s esophagus or esophageal adenocarcinoma. Gastroenterology 2001; 121: 1281–1285. [DOI] [PubMed] [Google Scholar]
- 62. Campos GMR, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001; 136: 1267–1273. [DOI] [PubMed] [Google Scholar]
- 63. Cameron AJ. Barrett’s esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999; 94: 2054–2059. [DOI] [PubMed] [Google Scholar]
- 64. Sarr MG, Hamilton SR, Marrone GC, et al. Barrett’s esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985; 149: 187–193. [DOI] [PubMed] [Google Scholar]
- 65. Ringhofer C, Lenglinger J, Izay B, et al. Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr 2008; 120: 350–359. [DOI] [PubMed] [Google Scholar]
- 66. Amano Y, Kushiyama Y, Yuki T, et al. Prevalence of and risk factors for Barrett’s esophagus with intestinal predominant mucin phenotype. Scand J Gastroenterol 2006; 41: 873–879. [DOI] [PubMed] [Google Scholar]
- 67. Grassi A, Giannarelli D, Iacopini F, et al. Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett’s esophagus. J Exp Clin Cancer Res 2006; 25: 297–302. [PubMed] [Google Scholar]
- 68. Yilmaz N, Tuncer K, Tunçyürek M, et al. The prevalence of Barrett’s esophagus and erosive esophagitis in a tertiary referral center in Turkey. Turk J Gastroenterol 2006; 17: 79–83. [PubMed] [Google Scholar]
- 69. Wang A, Mattek NC, Corless CL, et al. The value of traditional upper endoscopy as a diagnostic test for Barrett’s esophagus. Gastrointest Endosc 2008; 68: 859–866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Dickman R, Levi Z, Vilkin A, et al. Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol 2010; 22: 135–138. [DOI] [PubMed] [Google Scholar]
- 71. Souza RF, Spechler SJ. Mechanisms and pathophysiology of Barrett oesophagus. Nat Rev Gastroenterol Hepatol 2022; 19: 605–620. [DOI] [PubMed] [Google Scholar]
- 72. Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am 2005; 89: 293–312. [DOI] [PubMed] [Google Scholar]
- 73. Kim GH, Kang DH, Song GA, et al. Gastroesophageal flap valve is associated with gastroesophageal and gastropharyngeal reflux. J Gastroenterol 2006; 41: 654–661. [DOI] [PubMed] [Google Scholar]
- 74. Kinoshita Y, Adachi K. Hiatal hernia and gastroesophageal flap valve as diagnostic indicators in patients with gastroesophageal reflux disease. J Gastroenterol 2006; 41: 720–721. [DOI] [PubMed] [Google Scholar]
- 75. Kahrilas PJ, Lin S, Chen J, et al. The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 1999; 44: 476–482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Hyun JJ, Bak YT. Clinical significance of hiatal hernia. Gut Liver 2011; 5: 267–277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Emerenziani S, Habib FI, Ribolsi M, et al. Effect of hiatal hernia on proximal oesophageal acid clearance in gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2006; 23: 751–757. [DOI] [PubMed] [Google Scholar]
- 78. Gordon C, Kang JY, Neild PJ, et al. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 719–732. [DOI] [PubMed] [Google Scholar]
- 79. Ye P, Li ZS, Xu GM, et al. Esophageal motility in patients with sliding hiatal hernia with reflux esophagitis. Chin Med J (Engl) 2008; 121: 898–903. [PubMed] [Google Scholar]
- 80. Kasapidis P, Vassilakis JS, Tzovaras G, et al. Effect of hiatal hernia on esophageal manometry and pH-metry in gastroesophageal reflux disease. Dig Dis Sci 1995; 40: 2724–2730. [DOI] [PubMed] [Google Scholar]
- 81. Holloway RH. Systemic pharmacomodulation of transient lower esophageal sphincter relaxations. Am J Med 2001; 111(Suppl. 8A): 178s–185s. [DOI] [PubMed] [Google Scholar]
- 82. Kahrilas PJ, Shi G, Manka M, et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118: 688–695. [DOI] [PubMed] [Google Scholar]
- 83. Paterson WG, Kolyn DM. Esophageal shortening induced by short-term intraluminal acid perfusion in opossum: a cause for hiatus hernia? Gastroenterology 1994; 107: 1736–1740. [DOI] [PubMed] [Google Scholar]
- 84. Dunne DP, Paterson WG. Acid-induced esophageal shortening in humans: a cause of hiatus hernia? Can J Gastroenterol 2000; 14: 847–850. [DOI] [PubMed] [Google Scholar]
- 85. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett’s oesophagus length. Gut 2001; 48: 310–313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Tharalson EF, Martinez SD, Garewal HS, et al. Relationship between rate of change in acid exposure along the esophagus and length of Barrett’s epithelium. Am J Gastroenterol 2002; 97: 851–856. [DOI] [PubMed] [Google Scholar]
- 87. Roman S, Kahrilas PJ. Mechanisms of Barrett’s oesophagus (clinical): LOS dysfunction, hiatal hernia, peristaltic defects. Best Pract Res Clin Gastroenterol 2015; 29: 17–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Zentilin P, Conio M, Mele MR, et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett’s oesophagus. Aliment Pharmacol Ther 2002; 16: 893–898. [DOI] [PubMed] [Google Scholar]
- 89. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg, 1999; 117: 572–580. [DOI] [PubMed] [Google Scholar]
- 90. Eusebi LH, Telese A, Cirota GG, et al. Systematic review with meta-analysis: risk factors for Barrett’s oesophagus in individuals with gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther 2021; 53: 968–976. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplemental material, sj-docx-1-tag-10.1177_17562848231219234 for Association between hiatal hernia and Barrett’s esophagus: an updated meta-analysis with trial sequential analysis by Shaoze Ma, Zhenhua Tong, Yong He, Yiyan Zhang, Xiaozhong Guo and Xingshun Qi in Therapeutic Advances in Gastroenterology





